Helix Nanotechnologies
YC W17Boston, US · 22 employees · 6 known investors
Helix Nanotechnologies develops mRNA-based therapeutics for disease treatment and environmental applications, currently advancing a COVID-19 vaccine candidate for immunocompromised patients and testing interventions targeting climate challenges.
AI & Machine LearningBiotechHealthtechArtificial IntelligenceGenomicsNanotechnologyin /company@helixnano
Founders & leadership· Y Combinator alumni (W17)
Nikolai EroshenkoinFounder/CSO